Még nem toboroz
A study on stopping versus continuing beta-blockers in patients with hypertrophic cardiomyopathy treated with mavacamten
2026-526612-36-00· 4. fázis· Ziekenhuis Oost Limburg· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Még nem toboroz
Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)
NCT07782112· 3. fázis· Ente Ospedaliero Cantonale, Bellinzona· Forrás
Contact: Philippe Bulens, MD
Toboroz
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
2026-526139-20-00· 3. fázis· Kardigan Inc.· Forrás
Toboroz
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
NCT07587658· 4. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
2026-525489-23-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
NCT07473128· 3. fázis· Pharmacosmos A/S· Forrás
Toboroz
A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
NCT07625215· 2. fázis· Bayer· Forrás
Toboroz
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07771465· 3. fázis· Kardigan, Inc.· Forrás
Contact: Kardigan Clinical Trial Team
Toboroz
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
NCT07566052· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
2025-522818-23-00· 3. fázis· Zai Lab (US) LLC· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )
2024-519818-31-01· 3. fázis· Genmab A/S· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270· 3. fázis· Genmab· Forrás
Toboroz
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
A trial investigating partial withdrawal of heart failure therapy in patients with heart failure in remission.
2025-522560-32-01· 4. fázis· Ziekenhuis Oost Limburg· Forrás
Toboroz
A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy.
2025-522553-19-00· 2/3. fázis· Kardigan Inc.· Forrás
Toboroz
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
NCT07368998· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
A phase 3 efficacy and safety study of fosmanogepix for the treatment of adult patients with invasive mold infections
2024-516216-16-00· 3. fázis· Basilea Pharmaceutica International AG Allschwil· Forrás
Toboroz
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07210723· 2/3. fázis· Kardigan, Inc.· Forrás
Contact: Kardigan Clinical Trial Team
Toboroz
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177· 2. fázis· Genmab· Forrás
Toboroz
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· 3. fázis· Eli Lilly and Company· Forrás
Contact: Jeroen Mebis (principal investigator)
Toboroz
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187· 2/3. fázis· AbbVie· Forrás
Toboroz
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174· 2. fázis· AbbVie· Forrás
Toboroz
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782· 1/2. fázis· AstraZeneca· Forrás
Toboroz
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037· 3. fázis· AstraZeneca· Forrás
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· 3. fázis· ImmunityBio, Inc.· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· 3. fázis· Pfizer· Forrás
Toboroz
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· 3. fázis· Pfizer· Forrás
Toboroz
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
2024-520050-38-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Adult Participants with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
2024-518586-10-00· 2/3. fázis· AbbVie Deutschland GmbH & Co. KG· Forrás
Toboroz
A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter
NCT07116525· Biosense Webster, Inc.· Forrás
Toboroz
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
NCT06784466· Arga Medtech SA· Forrás
Contact: Johan Vijgen, MD
Toboroz
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· 3. fázis· Pfizer· Forrás
Toboroz
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION)
2024-519521-37-01· 2/3. fázis· Corxel Pharmaceuticals Co. Ltd.· Forrás
Toboroz
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634· 3. fázis· Celcuity Inc· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
2024-515884-69-00· 3. fázis· Gilead Sciences Inc.· Forrás
Toboroz
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903· 3. fázis· Alnylam Pharmaceuticals· Forrás
Toboroz
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
NCT05815927· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Toboroz
Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume
NCT06719440· Cliniques universitaires Saint-Luc- Université Catholique de Louvain· Forrás
Contact: Secretary office
Toboroz
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· 3. fázis· Mirati Therapeutics Inc.· Forrás
Fut, nem toboroz
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790· 3. fázis· Arrowhead Pharmaceuticals· Forrás
Toboroz
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834· 3. fázis· Gilead Sciences· Forrás
Showing 50 of 129.